TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE

Date:**07-08- 2026**

The General Manager
Department of Corporate Services,
BSE Ltd., Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526139

Dear Sir / Madam,

Sub: **Outcome of the Meeting of the Board of Directors held on August 07, 2026**.

This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of the Company.

At a meeting of the Board of Directors of the company held on 07th August 2026 the following decisions have been taken:

1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended **30th June 2026**.
2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended **30th June 2026**.
3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year **2025-26**, subject to obtaining the necessary approval from the Registrar of Companies, wherever applicable.
4) The Board considered and approved the appointment of M/s. Manisha Dubey & Associates, as Internal Auditors of the Company for the financial year **2026-27**.

The meeting of the Board of Directors commenced at **11:00 A.M.** and concluded at **11:30 A.M**

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

DR. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Encls: as above

Plot 69 &70 , IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065

Disclosure pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr.No	Particulars	Internal Auditors
1	Name of Auditors	M/s. **Manisha Dubey & Associates**, Chartered Accountants (Proprietor: Ms. Manisha Dubey), Internal Auditors
2	Reason for change: Appointment	Appointment of M/s. **Manisha Dubey& Associates,** a Peer Reviewed Firm of Chartered Accountant in Practice, having Membership No.212664, as Internal Auditor of the Company.
3	Date of appointment and term of appointment	The Board at its meeting held on August 07, 2026, approved the appointment of M/s. Manisha Dubey & Associates, Chartered Accountant, as Internal Auditors of the Company for the financial year **2026-27.**
4	Brief profile (in case of appointment)	Ms. Manisha Dubey, Sole Proprietor firm of Chartered Accountant. Ms. Manisha Dubey has more than 24 years "M/s Manisha Dubey & Associates", is a Chartered Accountants firm having extensive experience in internal audit and Internal Financial Controls reviews.
5	Disclosure of relationships between directors (in case of appointment)	Not applicable

Plot 69 &70 , IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended	Year Ended
		30-06-2026 (Unaudited)	31-03-2026 (Unaudited)	30-06-2025 (Unaudited)	30-06-2026 (Unaudited)	30-06-2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from operations	6.00	5.45	4.95	6.00	4.95	21.12
2	Other income (net)	0.00	14.99	0.00	0.00	0.00	14.99
3	**Total income (1 + 2)**	**6.00**	**20.43**	**4.95**	**6.00**	**4.95**	**36.11**
4	**EXPENSES**						
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.37	3.38	4.72	3.37	4.72	14.73
	Finance costs	28.95	27.68	24.55	28.95	24.55	106.02
	Depreciation and amortisation expense	4.13	4.98	4.98	4.13	4.98	19.91
	Other expenses	8.45	30.09	14.07	8.45	14.07	60.74
	Total expenses	**44.90**	**66.13**	**48.32**	**44.90**	**48.32**	**201.40**
5	**Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00	0.00
7	**Profit before tax (5 - 6)**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
8	**Tax expense**						
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total tax expense	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
9	**Profit for the year (7 - 8)**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
10	**Other comprehensive income**						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
11	**Total comprehensive income for the year (9 +**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
12	**Earnings per equity share**						
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.05)	(0.06)	(0.06)	(0.05)	(0.06)	(0.22)
	Diluted (Rs.)	(0.05)	(0.06)	(0.06)	(0.05)	(0.06)	(0.22)

Notes:

1. SECURITIES APPELLATE TRIBUNAL (SAT): The matter has been adjourned from 14th July 2026 to 17th August 2026.
2. APPELLATE TRIBUNAL (ED), NEW DELHI: The process of hearing against the order passed by ED Adjudication Officer has started and heard our side of argument on 23rd July 2026 and adjourned further to 10th September 2026.
3. SBIRI / BIRAC: There has been no further communication from BIRAC subsequent to the last board meeting on 14th November 2025.
4. NITIN DIDWANIA: The order in this matter was passed on 8th July asking an amount of Rs.92,99,250/- to be paid with an interest of 6% per annum on the principal amount of originally taken loan of Rs.25 lacs. Aggrieved by this order, we have filed an appeal at the Hon'ble High Court of Bombay Commercial Division.
5. CUSTOMS & EXCISE DEPARTMENT: There has been no further development on this matter since the last board meeting
6. NCLT: Our matter came up for hearing on 8th July 2026 and adjourned to 23rd September 2026.
7. COMPLAINTS: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0
8. AUDIT REVIEW: The auditors have carried out a limited review of the financial results for the quarter ended 30th June 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 7th August 2026

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 07/08/2026
Place:Hyderabad

TRANSGENE BIOTEK LIMITED
Notes forming part of the Standalone financial statements

Other expenses **(In Lakhs)**

Particulars	For the Period ended on 30th June 2026
Advertisement	0.13
BSE Listing & Annual Custody fee	4.93
Bank charges	0.00
BSNL Fiber net	0.02
Directors sitting fee	0.15
Legal and Professional Charges	2.98
Office Expenses	0.17
Rates, taxes and duties	0.05
Repairs and maintenance	0.02
Telephone Expenses	0.02
Transport charges	0.00
Total	**8.45**

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 07/08/2026
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended	Year Ended
		30-06-2026 (Unaudited)	31-03-2026 (Unaudited)	30-06-2025 (Unaudited)	30-06-2026 (Unaudited)	30-06-2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from operations	6.00	5.45	4.95	6.00	4.95	21.12
2	Other income (net)	0.00	14.99	0.00	0.00	0.00	14.99
3	**Total income (1 + 2)**	**6.00**	**20.43**	**4.95**	**6.00**	**4.95**	**36.11**
4	**EXPENSES**						
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.37	3.38	4.72	3.37	4.72	14.73
	Finance costs	28.95	27.68	24.55	28.95	24.55	106.02
	Depreciation and amortisation expense	4.13	4.98	4.98	4.13	4.98	19.91
	Other expenses	8.45	30.09	14.07	8.45	14.07	60.74
	Total expenses	**44.90**	**66.13**	**48.32**	**44.90**	**48.32**	**201.40**
5	**Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00	0.00
7	**Profit before tax (5 - 6)**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
8	**Tax expense**						
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total tax expense	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
9	**Profit for the year (7 - 8)**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
10	**Other comprehensive income**						
	A Items that will not be reclassified subsequently to profit or loss (a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
11	**Total comprehensive income for the year (9 +**	**-38.90**	**-45.70**	**-43.37**	**-38.90**	**-43.37**	**-165.29**
12	**Earnings per equity share**						
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.05)	(0.06)	(0.06)	(0.05)	(0.06)	(0.22)
	Diluted (Rs.)	(0.05)	(0.06)	(0.06)	(0.05)	(0.06)	(0.22)

Notes:

1. SECURITIES APPELLATE TRIBUNAL (SAT): The matter has been adjourned from 14th July 2026 to 17th August 2026.
2. APPELLATE TRIBUNAL (ED), NEW DELHI: The process of hearing against the order passed by ED Adjudication Officer has started and heard our side of argument on 23rd July 2026 and adjourned further to 10th September 2026.
3. SBIRI / BIRAC: There has been no further communication from BIRAC subsequent to the last board meeting on 14th November 2025.
4. NITIN DIDWANIA: The order in this matter was passed on 8th July asking an amount of Rs.92,99,250/- to be paid with an interest of 6% per annum on the principal amount of originally taken loan of Rs.25 lacs. Aggrieved by this order, we have filed an appeal at the Hon'ble High Court of Bombay Commercial Division.
5. CUSTOMS & EXCISE DEPARTMENT: There has been no further development on this matter since the last board meeting
6. NCLT: Our matter came up for hearing on 8th July 2026 and adjourned to 23rd September 2026.
7. COMPLAINTS: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0
8. AUDIT REVIEW: The auditors have carried out a limited review of the financial results for the quarter ended 30th June 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 7th August 2026

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 07/08/2026
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Consolidated financial statements

Other expenses **(In Lakhs)**

Particulars	**For the Period ended on 30th June 2026**
Advertisement	0.13
BSE Listing & Annual Custody fee	4.93
Bank charges	0.00
BSNL Fiber net	0.02
Directors sitting fee	0.15
Legal and Professional Charges	2.98
Office Expenses	0.17
Rates, taxes and duties	0.05
Repairs and maintenance	0.02
Telephone Expenses	0.02
Transport charges	0.00
Total	**8.45**

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 07/08/2026
Place:Hyderabad

M/S VASAVI & CO
Chartered Accountants

Limited Review report

To
The Board of Directors,
M/s TRANSGENE BIOTEK LIMITED
Hyderabad

We have reviewed the accompanying statement of unaudited standalone financial results of M/s TRANSGENE BIOTEK LIMITED for the Quarter ended 30th June 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASAVI & CO,
Chartered Accountants
FRN 020965S

G.R.L.Vasavi

M/s. VASAVI & CO. 249259 Hyderabad Chartered Accountants

(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259

UDIN for this document is: 26249259BCRWKI6329
Place: Hyderabad
Date: 07/08/2026

#8-3-903/4/4, F No 201, Krishna Enclave, Road No 05, Nagarjuna Nagar, Srinagar Colony, Hyderabad – 500073, TG.
Contact No: +91 9652251341, Email: vasavinco@gmai.com

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Transgene Biotek Ltd ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter ended 30/06/2026 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/06/2026 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the following entities:

    1. Transgene Biotek HK Ltd - Subsidiary

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June 2026, as considered in the consolidated unaudited financial results.

For VASAVI & CO,
Chartered Accountants
FRN 020965S

G.R.L.Vasavi

M/s. VASAVI & CO, 249259 Hyderabad, Chartered Accountants

(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259

UDIN for this document is: 26249259BCRWKI6329

Place: Hyderabad
Date: 07/08/2026